TO STUDY AND ASSESS THE VALIDITY OF THE RISK OF MALIGNANCY INDEX(RMI-4) IN DISCRIMINATING BETWEEN BENIGN AND MALIGNANT OVARIAN MASSES

Introduction:The most fatal of all gynecological cancers is ovarian cancer. Of all gynecological cancers, it has the greatest fatality-to-case ratio. It is the 4th most prevalent cancer among women. The lifetime risk of being diagnosed with ovarian carcinoma is 1% to 1.5 %, with a nearly 0.5% chance of dying from it. Suboptimal primary cytoreductive surgery has great prognostic significance. The reason was because of inappropriate preoperative evaluation, which decides the kind of surgery being performed and the surgeons expertise of the surgeon in performing staging laparotomy if indicated. Hence, a gynecologist must be able to differentiate benign from the malignant ovarian mass. Several studies have revealed that the diagnosis of ovarian mass by investigations like Ultrasonogram, Doppler, MRI, CT has been proved to be uncertain despite the need for expertise. The goal of this study was to assess the ability of the Risk of Malignancy Index Scoring System (RMI- 4) in differentiating benign from malignant ovarian masses and to compare the scoring patterns to histopathological findings.